ABSTRACT
PET and SPECT imaging with radiolabelled antibodies (immunoPET/SPECT) has shown great potential, especially in the field of oncology, but also beyond. In this chapter, we will provide a general overview of the different applications of antibody-based radionuclide imaging in oncology. ImmunoPET/SPECT can play an important role during drug development – for example to study the in vivo biodistribution of new antibody-based drugs. Furthermore, in clinical practice it can potentially be used as a clinical decision-making tool in patients with cancer. The chapter will also provide basic background information about antibody structure and function, and the most commonly used radiolabelling strategies for antibodies. Furthermore, it will discuss practical aspects to consider when designing PET or SPECT imaging studies. Finally, the chapter describes different aspects that should be taken into account when interpreting immunoPET/SPECT scans, and examples will be provided as to how immunoPET/SPECT has been applied in research and clinical practice.
